Validation of Brief COPE to Evaluate Coping in Patients with Parkinson’s Disease and Care Partners

Summary

This study wants to validate a scale called the Brief COPE. This scale measures coping strategies in individuals with Parkinson's Disease (PD) and their care partners. Coping refers to the thoughts and behaviors people use to manage the challenges and stressors they face. Proper coping strategies are crucial for maintaining a good quality of life for people with PD.

The Brief COPE is a questionnaire that assesses coping methods for dealing with stressful life events. It has been used in various disorders and populations, but not in PD and care partners. By validating this scale, researchers want to provide a tool to understand and test coping strategies. The study will involve 200 participants, including 100 patients and 100 care partners.

The outcomes of this study will contribute to understanding better the coping strategies in PD. To improve the quality of care and support for patients and their care partners.

Eligibility

Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 100

Accepts healthy participants: Yes

Inclusion criteria:

- Inclusion criteria for patients with PD will contain patients of any age clinically diagnosed with PD at any stage of the disease, who are willing and able to provide informed consent.

Care partners with a Montreal Cognitive Assessment score of 20 or more.

Exclusion criteria:

- Patients with a score less than 10 on the Montreal Cognitive Assessment

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

karla.cantuflores@ucalgary.ca 403-919-7542

Principal investigator:

Veronica Bruno

Clinical trial:

No

REB-ID:

REB23-0925